These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33755971)

  • 41. Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.
    Lian Z; Du W; Zhang Y; Fu Y; Liu T; Wang A; Cai T; Zhu J; Zeng Y; Liu Z; Huang JA
    Thorac Cancer; 2020 Jul; 11(7):1934-1943. PubMed ID: 32433828
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Baicalein Enhances Radiosensitivity in Colorectal Cancer via JAK2/STAT3 Pathway Inhibition.
    Yu Q; Tang R; Mo W; Zhao L; Li L
    Chem Biol Drug Des; 2024 Aug; 104(2):e14611. PubMed ID: 39152534
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Salidroside suppresses the growth and invasion of human osteosarcoma cell lines MG63 and U2OS in vitro by inhibiting the JAK2/STAT3 signaling pathway.
    Huang L; Huang Z; Lin W; Wang L; Zhu X; Chen X; Yang S; Lv C
    Int J Oncol; 2019 Jun; 54(6):1969-1980. PubMed ID: 31081055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.
    Liu Y; Wang L; Wu Y; Lv C; Li X; Cao X; Yang M; Feng D; Luo Z
    Toxicology; 2013 Feb; 304():120-31. PubMed ID: 23313376
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3.
    Sun J; Du Y; Zhang X; Wang Z; Lin Y; Song Q; Wang X; Guo J; Li S; Nan J; Yang J
    Invest New Drugs; 2020 Aug; 38(4):1003-1011. PubMed ID: 31612426
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fraxetin inhibits the growth of colon adenocarcinoma cells via the Janus kinase 2/signal transducer and activator of transcription 3 signalling pathway.
    Ren S; Xing Y; Wang C; Jiang F; Liu G; Li Z; Jiang T; Zhu Y; Piao D
    Int J Biochem Cell Biol; 2020 Aug; 125():105777. PubMed ID: 32504672
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anticancer effect of salidroside on colon cancer through inhibiting JAK2/STAT3 signaling pathway.
    Sun KX; Xia HW; Xia RL
    Int J Clin Exp Pathol; 2015; 8(1):615-21. PubMed ID: 25755753
    [TBL] [Abstract][Full Text] [Related]  

  • 48. B7‑H3 promotes cell migration and invasion through the Jak2/Stat3/MMP9 signaling pathway in colorectal cancer.
    Liu F; Zhang T; Zou S; Jiang B; Hua D
    Mol Med Rep; 2015 Oct; 12(4):5455-60. PubMed ID: 26151358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1.
    Lin B; Song X; Yang D; Bai D; Yao Y; Lu N
    Gene; 2018 May; 654():77-86. PubMed ID: 29454091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade.
    Yang Q; Ni L; Imani S; Xiang Z; Hai R; Ding R; Fu S; Wu JB; Wen Q
    Cancer Manag Res; 2020; 12():4937-4948. PubMed ID: 32606981
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.
    Qin T; Liu Z; Wang J; Xia J; Liu S; Jia Y; Liu H; Li K
    Cancer Biol Med; 2020 Aug; 17(3):753-767. PubMed ID: 32944404
    [No Abstract]   [Full Text] [Related]  

  • 52. Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma.
    Zhou W; Gao Y; Tong Y; Wu Q; Zhou Y; Li Y
    Pharmacol Res; 2021 Feb; 164():105392. PubMed ID: 33348023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway.
    Du W; Hong J; Wang YC; Zhang YJ; Wang P; Su WY; Lin YW; Lu R; Zou WP; Xiong H; Fang JY
    J Cell Mol Med; 2012 Aug; 16(8):1878-88. PubMed ID: 22050790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.
    Liang J; Jin Z; Kuang J; Feng H; Zhao Q; Yang Z; Zhan L; Shen B; Yan J; Cai W; Cheng X; Qiu W
    Br J Cancer; 2021 Aug; 125(3):390-401. PubMed ID: 34088989
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro.
    Zhu WQ; Wang J; Guo XF; Liu Z; Dong WG
    World J Gastroenterol; 2016 Apr; 22(16):4149-59. PubMed ID: 27122665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance.
    Park SY; Lee CJ; Choi JH; Kim JH; Kim JW; Kim JY; Nam JS
    J Exp Clin Cancer Res; 2019 Sep; 38(1):399. PubMed ID: 31511084
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
    Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eriocalyxin B blocks human SW1116 colon cancer cell proliferation, migration, invasion, cell cycle progression and angiogenesis via the JAK2/STAT3 signaling pathway.
    Lu YM; Chen W; Zhu JS; Chen WX; Chen NW
    Mol Med Rep; 2016 Mar; 13(3):2235-40. PubMed ID: 26795301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway.
    He C; Wu T; Hao Y
    Biochem Biophys Res Commun; 2018 Sep; 503(4):3093-3099. PubMed ID: 30146257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
    Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
    BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.